Traditional CRISPR is a genetic engineering tool that allows scientists to easily delete specific genes in an organism’s DNA and assess their role and importance. It has become a cornerstone technology in cancer research.
A newer frontier is CRISPR activation, a technique that enables the activation of specific genes. It offers valuable insights into the roles of certain genes in cancer and other genetic disorders.
A team of researchers from the Olivia Newton-John Cancer Research Institute (ONJCRI), WEHI and Genentech, a member of the Roche Group, used a new CRISPR activation tool called Partita and combined it with a mouse model of aggressive lymphoma.